Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Cellerant Therapeutics

Request full access

Cell and antibody immunotherapies for hematologic malignancies

San Carlos, United StatesFounded 2003Biotechnology

About Cellerant Therapeutics

Cellerant Therapeutics, Inc. is a clinical-stage biotechnology company founded in 2003 and headquartered in San Carlos, California. The company focuses on developing cell- and antibody-based immunotherapies to treat hematologic malignancies and other blood-related disorders.

The former President and CEO, Ram Mandalam, Ph.D., has over thirty years of experience in cell therapy and biologics development. Before leading Cellerant, he was the Executive Director of Product Development at Geron Corporation and held research and development roles at Aastrom Biosciences. Under his leadership, Cellerant established a pipeline of therapeutic candidates and advanced from an early-stage to a clinical-stage company. The company has raised a total of $51 million over 15 funding rounds from investors including Allen & Company and SBIR.

Cellerant's product portfolio is based on regulating the hematopoietic (blood-forming) system. One of its primary products is romyelocel-L (CLT-008), a universal, off-the-shelf myeloid progenitor cell therapy designed to reduce infection risk during neutropenia, a common side effect of chemotherapy. A key advantage of romyelocel-L is that it does not require HLA matching between donor and recipient. In a Phase 2 clinical trial for patients with Acute Myeloid Leukemia (AML), romyelocel-L demonstrated a reduction in infections and hospital stay duration. The FDA has granted it Regenerative Medicine Advanced Therapy (RMAT) designation. The therapy was also developed for Acute Radiation Syndrome (ARS) under a contract with the Biomedical Advanced Research and Development Authority (BARDA).

The company is also advancing two antibody-drug conjugate (ADC) products. CLT030 is an ADC that targets the CLL1 protein, which is highly expressed on AML leukemic stem cells (LSCs) but not on normal hematopoietic stem cells. This specificity allows CLT030 to selectively kill cancer cells and LSCs, which are often responsible for disease relapse, while sparing healthy cells. A second ADC, CSC012-ADC, is in development for other hematologic malignancies and solid tumor indications. In 2020, Cantargia AB acquired a patent portfolio from Cellerant related to the IL1RAP protein, a target for antibody therapy in leukemia.

Source: Dealroom company data

At a glance

Status
Operational
Founded
2003
Headquarters
San Carlos, United States
Employees
17
Open positions
None listed
Dealroom signal
40.5/100
Sector
Biotechnology
Client focus
B2B

Funding history

10 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
GRANTOther financing Sep 2016 $1.5M — Undisclosed —
DEBTDebt Apr 2016 $2M — Undisclosed —
Showing the latest 2 of 10 recorded eventsBook a demo for the full funding history →

Growth signals

Cellerant Therapeutics website traffic

Latest recorded traffic for Cellerant Therapeutics is 50 monthly website visits, down 50% over the last three months. Cellerant Therapeutics's team grew 0% over the past year.

Latest monthly visits50 3-month web change-50% 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

CompanyHeadquartersStatusEmployeesTotal fundingValuation
MyhCueModern cloud based pharmacy management system for pharmacies, clinic management system, ehr platform for doctors & patients Singapore, Singapore Operational 52 — —
Health OutcomeFirst platform for patients to rate and review their treatment experiences and help find treatments that cure Palo Alto, United States Operational
Douglas ScientificDouglas Scientific is dedicated to making our world a better place by delivering innovative laboratory automation Alexandria, United States Acquired
Leap the PondCompany delivers intacct based accounting solutions to growing organizations that have big plans Milford, United States Operational
BioIT SolutionsBioIT Solutions enables its Life Sciences partners to focus on core activities by removing information management obstacles Washington DC, United States Operational
Navix DiagnostixA unique solution to health care providers seeking to increase the effectiveness of their diagnostic services Taunton, United States Operational
MMJRecsThe platform that enables California medical-cannabis patients to obtain doctor recommendations via their mobile devices or online San Francisco, United States Operational
Endonovo TherapeuticsBiotechnology company developing off-the-shelf regenerative products Los Angeles, United States Operational
Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Cellerant Therapeutics in the San Carlos ecosystem

Live from Dealroom

The Cellerant Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

4 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A4 investors entered at this stage

Team profiled 14 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇳🇬 Nigeria50%
🇺🇸 United States50%
2 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Cellerant Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Cellerant Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.